Is high-intensity focused ultrasound (HIFU) an option for neoadjuvant therapy for borderline resectable pancreatic cancer patients? - a systematic review.

Nadya Stanislavova Martin Karamanliev Tsvetomir Ivanov Tsanko Yotsov Kun Zhou Dobromir Dimitrov

Published in: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2021)

HIFU is found to be safe and feasible in locally advanced and metastatic pancreatic cancer with proven downstaging and downsizing effects. Further research on role of HIFU ablation as a neoadjuvant treatment for borderline resectable pancreatic cancer is needed.

Keyphrases

high intensity
locally advanced
rectal cancer
squamous cell carcinoma
neoadjuvant chemotherapy
phase ii study
radiation therapy
resistance training
small cell lung cancer
combination therapy
open label
liver metastases